journal
MENU ▼
Read by QxMD icon Read
search

Therapeutic Apheresis and Dialysis

journal
https://www.readbyqxmd.com/read/28195403/self-care-on-hemodialysis-behaviors-with-the-arteriovenous-fistula
#1
Clemente Neves Sousa, Patrícia Marujo, Paulo Teles, Marta Nunes Lira, Maria Eulália Leite Mota Novais
End stage renal disease (ESRD) patients should be educated to maintain and preserve the arteriovenous fistula (AVF) in the best condition. The purpose of this work was to evaluate self-care frequency and factors that influenced such frequency. A prospective study was performed in 101 hemodialysis patients. Self-care behaviors were measured with the Scale of Assessment of Self-Care Behaviours with Arteriovenous Fistula in Hemodialysis. A regression model was used to determine the relevant predictors of self-care frequency and their influence...
February 14, 2017: Therapeutic Apheresis and Dialysis
https://www.readbyqxmd.com/read/28194903/vitamin-k-antagonist-therapy-is-a-risk-factor-for-ulcer-development-and-death-among-dialyzed-patients
#2
Andreana De Mauri, Massimo Torreggiani, Marco Brambilla, Doriana Chiarinotti
Peripheral artery disease is a common complication among dialyzed patients. Since Vitamin K antagonists promote metastatic calcifications and these are the main determinants of vascular damage, we investigated their role in the development of lower limb ulcers in dialyzed patients. We retrospectively enrolled 316 dialyzed patients, aged 68 ± 15 years, 65% male, 32% diabetic, 43% with ischemic heart disease and followed them for 36 ± 25 months. 60 patients assumed Vitamin K antagonists: they were older, with a higher prevalence of heart disease, at greater risk of death and they developed more ulcers and underwent more lower limb amputations compared to the rest of our cohort...
February 14, 2017: Therapeutic Apheresis and Dialysis
https://www.readbyqxmd.com/read/28194884/long-term-safety-and-efficacy-of-bixalomer-in-hyperphosphatemic-patients-with-chronic-kidney-disease-not-on-dialysis
#3
Tadao Akizawa, Junko Tsukada, Chisato Kameoka, Kentarou Kuroishi, Yusuke Yamaguchi
Bixalomer, a metal-free, nonabsorbable phosphate binder, is approved in Japan to treat hyperphosphatemia in dialysis patients. Bixalomer is effective and has a favorable safety profile in predialysis patients with hyperphosphatemia. This study examined the long-term effectiveness and safety of bixalomer in predialysis patients with hyperphosphatemia. This was a 48-week, multicenter, open-label, phase 3 study in Japanese predialysis patients with hyperphosphatemia. Patients received bixalomer at an initial dose of 1500 mg/day, which was titrated to a maximum of 7500 mg/day depending on patients' serum phosphorus responses to bixalomer...
February 14, 2017: Therapeutic Apheresis and Dialysis
https://www.readbyqxmd.com/read/28195402/regional-citrate-anticoagulation-beware-of-recirculation-phenomenon
#4
LETTER
Alexis Chenouard, Jean-Michel Liet
No abstract text is available yet for this article.
February 13, 2017: Therapeutic Apheresis and Dialysis
https://www.readbyqxmd.com/read/28185420/successful-treatment-of-atypical-hemolytic-uremic-syndrome-with-therapeutic-plasma-exchange-in-a-3-8-kg-neonate
#5
LETTER
May Abdullah Almoshary, Reham Alswyeh, Burhan Mohammed B Edrees
No abstract text is available yet for this article.
February 10, 2017: Therapeutic Apheresis and Dialysis
https://www.readbyqxmd.com/read/28185412/differences-in-clinical-and-pathological-features-of-renal-cell-carcinoma-between-japanese-patients-after-kidney-transplantation-and-those-on-hemodialysis
#6
Toshio Takagi, Tsunenori Kondo, Masayoshi Okumi, Hideki Ishida, Kazunari Tanabe
We compared the clinical features, pathological features, and prognoses of patients with renal cell carcinoma (RCC) arising in the native kidney after kidney transplantation (RCC-transplant) or on hemodialysis (RCC-HD), and analyzed predictive factors for survival at a Japanese single institution. This cohort included 42 patients in the RCC-transplant group and 467 patients in the RCC-HD group. RCC-transplant patients were younger (53 years vs. 56 years, P = 0.0358) and had less frequent symptoms (12% vs...
February 10, 2017: Therapeutic Apheresis and Dialysis
https://www.readbyqxmd.com/read/28185407/effects-of-sodium-concentration-and-dialysate-temperature-changes-on-blood-pressure-in-hemodialysis-patients-a-randomized-triple-blind-crossover-clinical-trial
#7
Hossein Ebrahimi, Mahboobeh Safavi, Marzieh Hossein Saeidi, Mohammad Hassan Emamian
The present study investigated the effects of different temperatures and sodium dialysate concentration on blood pressure in hemodialysis patients. Following Williams' design, hemodialysis patients were randomly assigned into four dialysis modes. Dialysate temperature was set at 37°C for modes A and C and, 35°C for modes B and D. Sodium concentration was set at 138 mmol/L in modes A and B, while it changed from 150 mmol/L to 138 mmol/L in modes C and D. Using analysis of variance for repeated measures, the mean values of systolic and diastolic blood pressure were investigated...
February 10, 2017: Therapeutic Apheresis and Dialysis
https://www.readbyqxmd.com/read/28185405/evaluation-of-long-term-combination-therapy-with-peritoneal-dialysis-and-hemodialysis
#8
Reo Kanda, Hiroaki Io, Junichiro Nakata, Yuko Makita, Yu Sasaki, Mayumi Matsumoto, Keiichi Wakabayashi, Yasuhiko Tomino, Yusuke Suzuki
It is well known that a combination therapy with peritoneal dialysis (PD) and hemodialysis (HD) is feasible and may improve clinical status in patients for whom adequate solute and fluid removal is difficult to achieve with PD alone. The objective of the present study was to evaluate whether the therapy is useful in the likelihood of long-term peritoneal membrane and cardiac function. The therapy was 6 days of PD and one session of HD per week. Physical, biochemical, dialysate-to-plasma ratio of creatinine (D/P Cr), arteriovenous fistula (AVF) blood flow, and left ventricular mass index (LVMI) data were prospectively analyzed in 30 patients with measurements performed at 0 and 6 months, and for 21 patients, 12 or 18 months after initiation of the therapy...
February 10, 2017: Therapeutic Apheresis and Dialysis
https://www.readbyqxmd.com/read/28156087/mourning-the-loss-of-dr-akio-kawamura
#9
Kazutaka Kukita
No abstract text is available yet for this article.
February 2017: Therapeutic Apheresis and Dialysis
https://www.readbyqxmd.com/read/28156086/upcoming-meetings-therapeutic-apheresis-and-dialysis-february-2017
#10
(no author information available yet)
No abstract text is available yet for this article.
February 2017: Therapeutic Apheresis and Dialysis
https://www.readbyqxmd.com/read/28156085/the-isfa-wishes-to-acknowledge-the-following-2016-corporate-sponsors
#11
(no author information available yet)
No abstract text is available yet for this article.
February 2017: Therapeutic Apheresis and Dialysis
https://www.readbyqxmd.com/read/28105770/does-peritoneal-protein-transport-increase-with-peritoneal-dialysis-therapy-duration-and-lead-to-extracellular-water-overload-in-peritoneal-dialysis-patients
#12
Cate Goodlad, Andrew Davenport
Faster peritoneal transport status has been associated with adverse outcomes for peritoneal dialysis (PD) patients. Peritoneal protein clearance, through large pores, may be a surrogate marker of local inflammation. We wished to determine whether peritoneal protein transport increased with PD duration or was associated with extracellular water (ECW) expansion. We studied the relationships between 4 h Dialysate (D)/Serum (S) protein and ECW excess, using multifrequency bioelectrical impedance assessments, in 103 PD patients with up to 4 years of prospectively collected peritoneal equilibrium test (PET) results...
February 2017: Therapeutic Apheresis and Dialysis
https://www.readbyqxmd.com/read/28093894/importance-of-body-water-in-the-efficacy-of-convective-solute-transport-in-online-hemodiafiltration
#13
Nicolás Macías, Alba Santos García, Almudena Vega Martínez, Soraya Abad Estébanez, Marian Goicoechea Diezhandino, Juan Manuel López Gómez
High-volume online hemodiafiltration (OL-HDF) has been associated with improved patient survival compared to conventional hemodialysis in recent trials, where the importance of convective volume (CV) in this benefit is noted. The purpose of this study was to determine the corporal composition parameters influencing the efficacy of CV in the removal of different molecular weight (MW) molecules. Demographic data, corporal composition parameters with bioimpedance spectroscopy, dialysis features and the reduction rates of different MW molecules in a four-hour OL-HDF session were collected in 61 patients...
February 2017: Therapeutic Apheresis and Dialysis
https://www.readbyqxmd.com/read/28078749/total-phosphate-elimination-is-negatively-associated-with-increased-serum-fibroblast-growth-factor-23-levels-in-patients-who-undergo-peritoneal-dialysis
#14
Shunsuke Yamada, Kazuhiko Tsuruya, Masanori Tokumoto, Hisako Yoshida, Narihito Tatsumoto, Hiroaki Ooboshi, Takanari Kitazono
As fibroblast growth factor 23 (FGF23) has been shown to induce cardiovascular disease directly in patients with chronic kidney disease, identification of factors and treatments that can modulate serum FGF23 (sFGF23) level is clinically important. This retrospective longitudinal study investigated factors that modulate sFGF23 in 49 patients who underwent peritoneal dialysis (PD). sFGF23 ratio (sFGF23 at 18 months/baseline sFGF23) was used as an indicator of changes in sFGF23 level. Total phosphate elimination was the sum of both renal phosphate excretion and dialysate phosphate elimination...
February 2017: Therapeutic Apheresis and Dialysis
https://www.readbyqxmd.com/read/28078747/granulocyte-monocyte-apheresis-as-an-adjuvant-therapy-to-anti-tumor-necrosis-factor-drugs-for-ulcerative-colitis
#15
Iago Rodríguez-Lago, Laura Gómez-Irwin, Encarnación Fernández, Rebeca Higuera, José Luis Cabriada
Biologic anti-tumor necrosis factor (TNF) drugs have demonstrated their efficacy for the treatment of ulcerative colitis. Nevertheless, some patients will not respond to this therapy or will develop loss of response. Leukapheresis is the main non-pharmacological therapy for some immune-mediated diseases. The aim of our study was to describe our experience with this therapy in ulcerative colitis patients after loss of response to anti-TNF treatment. Leukapheresis was indicated in four patients with left-sided or extensive colitis because of partial response to biological therapy or secondary loss of response to it...
February 2017: Therapeutic Apheresis and Dialysis
https://www.readbyqxmd.com/read/28078733/therapeutic-apheresis-in-immunologic-renal-and-neurological-diseases
#16
REVIEW
Rolf Bambauer, Reinhard Latza, Daniel Burgard, Ralf Schiel
Since the mid 1970s, when membrane modules became available, plasma separation techniques have gained in importance especially in the past few years. The advantages of this method are a complete separation of the corpuscular components from the plasma and due to increased blood flow rate and higher efficacy. Systemic autoimmune diseases based on an immune pathogenesis produce autoantibodies and circulating immune complexes, which cause inflammation in the tissues of various organs. In most cases, these diseases have a poor prognosis without treatment...
February 2017: Therapeutic Apheresis and Dialysis
https://www.readbyqxmd.com/read/28067473/role-of-uremic-toxins-on-apoptosis-with-varying-periods-of-hemodialysis
#17
Zeynep Hünkerler, Tülay Köken, Buğra Koca, Ahmet Kahraman
Increased apoptotic cell death in uremic patients has been confirmed by a variety of studies. The present study aimed to investigate the effect of uremic toxins and duration of hemodialysis (HD) therapy on apoptosis by means of measuring serum caspase cleaved CK18 (CCCK-18) levels. Seventy chronic HD patients were recruited and divided into three groups with differing periods of HD, from 6 months to 10 years. Twelve healthy subjects served as controls. Serum CCCK-18 level was found significantly higher in HD patient groups (Group 2; 189 ± 71 IU/L, Group 3; 182 ± 65 IU/L, Group 4; 204 ± 111 IU/L) as compared to the control group (122 ± 20 U/L) (P < 0...
February 2017: Therapeutic Apheresis and Dialysis
https://www.readbyqxmd.com/read/28067459/surgical-and-oncologic-outcomes-of-laparoscopic-radical-nephrectomy-for-non-metastatic-renal-cancer-in-long-term-dialysis-patients
#18
Kenji Omae, Tsunenori Kondo, Toshio Takagi, Junpei Iizuka, Hirohito Kobayashi, Yasunobu Hashimoto, Kazunari Tanabe
This study aimed to compare the outcomes of laparoscopic radical nephrectomy (LRN) between patients undergoing dialysis for ≤240 and >240 months. Data from all dialysis patients with non-metastatic renal cell carcinoma (RCC) treated with LRN between 2008 and 2015 in our hospital were evaluated retrospectively. Patients were divided into two groups, shorter- and longer-term dialysis patients, according to the preoperative duration of dialysis (≤240 vs. >240 months). Of 174 patients, 58 (33.3%) were on longer-term dialysis...
February 2017: Therapeutic Apheresis and Dialysis
https://www.readbyqxmd.com/read/28025864/immunoadsorption-as-a-long-term-therapy-in-recurrent-focal-segmental-glomerulosclerosis-after-renal-transplantation
#19
LETTER
Silvius Frimmel, Steffen R Mitzner, Sebastian Koball
No abstract text is available yet for this article.
February 2017: Therapeutic Apheresis and Dialysis
https://www.readbyqxmd.com/read/27995744/online-hemodiafiltration-reduces-bisphenol-a-levels
#20
Borja Quiroga, Ricardo J Bosch, Ruth A Fiallos, Marta Sánchez-Heras, Nuria Olea-Herrero, Pilar López-Aparicio, Carmen Muñóz-Moreno, Miguel Angel Pérez-Alvarsan, Gabriel De Arriba
Several uremic toxins have been identified and related to higher rates of morbidity and mortality in dialysis patients. Bisphenol A (BPA) accumulates in patients with chronic kidney disease. The aim of this study is to demonstrate the usefulness of online hemodiafiltration (OL-HDF) in reducing BPA levels. Thirty stable hemodialysis patients were selected to participate in this paired study. During three periods of 3 weeks each, patients were switched from high-flux hemodialysis (HF-HD) to OL-HDF, and back to HF-HD...
February 2017: Therapeutic Apheresis and Dialysis
journal
journal
40470
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"